PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00598286
Recruitment Status : Completed
First Posted : January 21, 2008
Last Update Posted : October 27, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:
The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.

Condition or disease Intervention/treatment Phase
CB1 Cannabinoid PET Brain Imaging Drug: [18F]FMPEP-d2 Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2
Study Start Date : January 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Efficacy of novel PET tracer for CB1 in brain imaging.

Secondary Outcome Measures :
  1. Distribution and variance of CB1 receptors in the brain of healthy controls.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  • All subjects must be healthy and aged 18-65 years, with history/physical exam, ECG, and laboratory tests within one year of the PET scan.
  • The volunteer must sign an informed consent form.


  • Current psychiatric illness, substance abuse including marijuana use, or severe systemic disease based on history and physical exam.
  • Laboratory tests with clinically significant abnormalities or positive urine toxicology screen.
  • Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual limits.
  • Pregnancy and breast feeding.
  • Claustrophobia.
  • Presence of ferromagnetic metal in the body or heart pacemaker.
  • Positive HIV test.
  • Employee of the investigative site or an immediate family member of an employee of the investigative site. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Employee of Eli Lilly and Company.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00598286

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Mental Health (NIMH)